康恩贝：康恩贝集团及一致行动人持股比例已降至10.48%

Core Viewpoint - Kang En Bei announced that its second-largest shareholder, Kang En Bei Group Co., Ltd., reduced its stake in the company due to funding needs for its own business development [1] Group 1: Shareholder Actions - On January 16, 2026, Kang En Bei Group sold 50,659,020 shares through a block trade, accounting for 1.998% of the company's total share capital [1] - The selling price was set at 4.25 yuan per share, resulting in a total reduction amount of 215 million yuan [1] - After the completion of this reduction, Kang En Bei Group's shareholding decreased from 9.044% to 7.043%, while the combined shareholding with its concerted actor, Hu Jiqiang, fell from 12.484% to 10.481% [1] Group 2: Compliance and Regulations - The equity change triggered a 1% threshold but did not reach the level that would require a mandatory tender offer [1] - The reduction was conducted in strict compliance with relevant laws, regulations, and commitments [1] - The controlling shareholder, Zhejiang Province Pharmaceutical Health Industry Group Co., Ltd., was the buyer of the reduced shares [1]